|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/04/16 NovaBay Pharmaceuticals, Inc. 10-K 12/31/15 81:8.7M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.37M
2: EX-10.19 Material Contract HTML 23K
3: EX-23.1 Consent of Experts or Counsel HTML 24K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
14: R1 Document And Entity Information HTML 53K
15: R2 Consolidated Balance Sheets HTML 99K
16: R3 Consolidated Balance Sheets (Parentheticals) HTML 37K
17: R4 Consolidated Statements of Operations and HTML 70K
Comprehensive Loss
18: R5 Consolidated Statements of Stockholders' Equity HTML 126K
19: R6 Consolidated Statements of Cash Flows HTML 111K
20: R7 Note 1 - Organization HTML 32K
21: R8 Note 2 - Summary of Significant Accounting HTML 108K
Policies
22: R9 Note 3 - Fair Value Measurements HTML 82K
23: R10 Note 4 - Inventory HTML 41K
24: R11 Note 5 - Property and Equipment HTML 47K
25: R12 Note 6 - Accrued Liabilities HTML 42K
26: R13 Note 7 - Related Party Notes Payable HTML 35K
27: R14 Note 8 - Commitments and Contingencies HTML 43K
28: R15 Note 9 - Warrant Liability HTML 91K
29: R16 Note 10 - Stockholders' Equity HTML 81K
30: R17 Note 11 - Equity-based Compensation HTML 193K
31: R18 Note 12 - License, Collaboration and Distribution HTML 92K
Agreements
32: R19 Note 13 - Employee Benefit Plan HTML 27K
33: R20 Note 14 - Income Taxes HTML 172K
34: R21 Note 15 - Subsequent Events HTML 30K
35: R22 Accounting Policies, by Policy (Policies) HTML 170K
36: R23 Note 2 - Summary of Significant Accounting HTML 70K
Policies (Tables)
37: R24 Note 3 - Fair Value Measurements (Tables) HTML 79K
38: R25 Note 4 - Inventory (Tables) HTML 40K
39: R26 Note 5 - Property and Equipment (Tables) HTML 45K
40: R27 Note 6 - Accrued Liabilities (Tables) HTML 41K
41: R28 Note 8 - Commitments and Contingencies (Tables) HTML 36K
42: R29 Note 9 - Warrant Liability (Tables) HTML 80K
43: R30 Note 10 - Stockholders' Equity (Tables) HTML 57K
44: R31 Note 11 - Equity-based Compensation (Tables) HTML 181K
45: R32 Note 12 - License, Collaboration and Distribution HTML 76K
Agreements (Tables)
46: R33 Note 14 - Income Taxes (Tables) HTML 173K
47: R34 Note 1 - Organization (Details) HTML 39K
48: R35 Note 2 - Summary of Significant Accounting HTML 45K
Policies (Details)
49: R36 Note 2 - Summary of Significant Accounting HTML 41K
Policies (Details) - Reconciliation of Basic and
Diluted EPS
50: R37 Note 2 - Summary of Significant Accounting HTML 32K
Policies (Details) - Antidilutive Securities
51: R38 Note 3 - Fair Value Measurements (Details) HTML 26K
52: R39 Note 3 - Fair Value Measurements (Details) - HTML 39K
Assets and Liabilities Measured at Fair Value on a
Recurring Basis
53: R40 Note 3 - Fair Value Measurements (Details) - Fair HTML 35K
Value of Warrant Liability
54: R41 Note 4 - Inventory (Details) - Inventory HTML 36K
55: R42 Note 5 - Property and Equipment (Details) HTML 26K
56: R43 Note 5 - Property and Equipment (Details) - HTML 41K
Property and Equipment Summary
57: R44 Note 6 - Accrued Liabilities (Details) - Accrued HTML 38K
Liabilities
58: R45 Note 7 - Related Party Notes Payable (Details) HTML 63K
59: R46 Note 8 - Commitments and Contingencies (Details) HTML 28K
60: R47 Note 8 - Commitments and Contingencies (Details) - HTML 39K
Future Minimum Lease Payments
61: R48 Note 9 - Warrant Liability (Details) HTML 78K
62: R49 Note 9 - Warrant Liability (Details) - The Key HTML 41K
Assumptions Used to Value the Warrants
63: R50 Note 10 - Stockholders' Equity (Details) HTML 149K
64: R51 Note 10 - Stockholders' Equity (Details) - HTML 40K
Outstanding Warrants
65: R52 Note 11 - Equity-based Compensation (Details) HTML 89K
66: R53 Note 11 - Equity-based Compensation (Details) - HTML 85K
Stock Options Outstanding
67: R54 Note 11 - Equity-based Compensation (Details) - HTML 44K
Weighted-average Assumptions Used in Determining
the Value of Options Granted
68: R55 Note 11 - Equity-based Compensation (Details) - HTML 33K
Summary of the Stock-based Compensation Expense
Included in Results of Operations
69: R56 Note 12 - License, Collaboration and Distribution HTML 104K
Agreements (Details)
70: R57 Note 12 - License, Collaboration and Distribution HTML 45K
Agreements (Details) - Deferred Revenue
71: R58 Note 14 - Income Taxes (Details) HTML 33K
72: R59 Note 14 - Income Taxes (Details) - Federal and HTML 35K
State Income Tax Provisions
73: R60 Note 14 - Income Taxes (Details) - Summary of HTML 50K
Deferred Tax Assets and Liabilities
74: R61 Note 14 - Income Taxes (Details) - Valuation HTML 26K
Allowance
75: R62 Note 14 - Income Taxes (Details) - Summary of Tax HTML 35K
Credit Carryforwards
76: R63 Note 14 - Income Taxes (Details) - Effective HTML 46K
Income Tax Rate Reconciliation
77: R64 Note 14 - Income Taxes (Details) - Unrecognized HTML 28K
Tax Benefit
78: R65 Note 15 - Subsequent Events (Details) HTML 57K
80: XML IDEA XML File -- Filing Summary XML 148K
79: EXCEL IDEA Workbook of Financial Reports XLSX 88K
8: EX-101.INS XBRL Instance -- nby-20151231 XML 1.96M
10: EX-101.CAL XBRL Calculations -- nby-20151231_cal XML 123K
11: EX-101.DEF XBRL Definitions -- nby-20151231_def XML 849K
12: EX-101.LAB XBRL Labels -- nby-20151231_lab XML 1.18M
13: EX-101.PRE XBRL Presentations -- nby-20151231_pre XML 810K
9: EX-101.SCH XBRL Schema -- nby-20151231 XSD 206K
81: ZIP XBRL Zipped Folder -- 0001437749-16-026877-xbrl Zip 201K
Exhibit 10.19
|
|
|
|
|
|
|
|
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/04/22 NovaBay Pharmaceuticals, Inc. S-1 5:953K RDG Filings/FA 12/01/21 NovaBay Pharmaceuticals, Inc. S-1 15:1.1M RDG Filings/FA 3/25/21 NovaBay Pharmaceuticals, Inc. 10-K 12/31/20 101:10M RDG Filings/FA 11/12/20 NovaBay Pharmaceuticals, Inc. 10-Q 9/30/20 89:10M RDG Filings/FA 8/06/20 NovaBay Pharmaceuticals, Inc. 10-Q 6/30/20 93:10M RDG Filings/FA |
